Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis.

Habteyes Hailu TolaKourosh Holakouie-NaieniTadesse LejisaMohammad Ali MansourniaMehdi YaseriEphrem TesfayeMillion Mola

Published in: PloS one (2019)

This review revealed that hypothyroidism is not a rare adverse drug reaction in MDR-TB patients on treatment. Ethionamide and PAS were the most frequently reported drugs that associated with the occurrence of hypothyroidism. Screening of hypothyroidism in MDR-TB patients on treatment is important while targeting patients on Ethionamide and PAS based treatment regimen.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
mycobacterium tuberculosis
prognostic factors
adverse drug
emergency department
replacement therapy
patient reported outcomes
drug delivery
smoking cessation
cancer therapy